Clinical Genomics, CSIRO settle on licence terms
Clinical Genomics and the CSIRO have signed a licensing agreement to allow the former to develop a blood test for bowel cancer.
The pair have signed a licence agreement based on patented and jointly discovered biomarkers for colorectal cancer.
The global agreement will allow Clinical Genomics to develop and promote the ColoVantage Plasma test.
The test screens for genes with cancer-specific signatures that can be detected in the blood of many patients with early-stage bowel cancer. It is designed as an alternative for patients who can’t and won’t undergo the current faecal occult bowel screening standard.
Clinical Genomics and the CSIRO have been collaborating on R&D focused on identifying and testing biomarkers for bowel tumour DNA, and the licensing deal is the culmination of this project.
“We’re pleased to achieve this collaborative research milestone with CSIRO and we are now set to make a contribution to bowel cancer screening in the real world,” Clinical Genomics CEO Dr Larry LaPointe said.
“We’ve already run a local pilot of the blood test here in NSW and the clinical testing around the patent-pending technology is encouraging.”
He said the company’s ultimate aim is to have ColoVantage Plasma integrated into protocols for bowel cancer screening around the world.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
